HIGHLIGHTS
- What: Although this trial demonstrated safety, further study is needed to support efficacy, clarification of the optimal dosing regimen, and the best timing for this intervention in the course of disease treatment. This study demonstrated a lack of rejection even in the presence of an intact immune system.
- Who: Julie O’Neal from the Autonomous University of Barcelona, Spain have published the paper: Traversing the bench to bedside journey for iNKT cell therapies, in the Journal: (JOURNAL)
- Future: Allogeneic pre-clinical studies along with current and future clinical trials are needed to clarify . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.